Lipitor Generics Problem Illustrates Need For Hatch-Waxman Reform, Academics Say
This article was originally published in The Pink Sheet Daily
Executive Summary
Even with revised use-it-or-lose it provisions, exclusivity parking is still prevalent and won't be prevented by banning "pay-for-delay" settlements, David Balto and Michael Carrier argue.
You may also be interested in...
Brand-Generic "Pay-For-Delay" Settlements Jump 63% In FY 2010
As a proportion of total settlements reported to FTC, however, the ones involving compensation to the generic firm remained the same.
Brand-Generic "Pay-For-Delay" Settlements Jump 63% In FY 2010
As a proportion of total settlements reported to FTC, however, the ones involving compensation to the generic firm remained the same.
Lipitor Generics: FDA Says Mylan Has No Standing To Sue (Until June 28?)
FDA is using a recent court decision involving ViroPharma’s antibiotic Vancocin to argue for dismissal of a Mylan Pharmaceuticals Inc. lawsuit that seeks a determination on generic marketing exclusivity rights for Pfizer’s Lipitor.